Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coherus BioSciences, Inc.

http://www.coherus.com/

Latest From Coherus BioSciences, Inc.

Keeping Track: US FDA Approves Zokinvy, Defers Liso-Cel, Declines ALKS 3831 And Zimhi; Two Biosimilars Filed

The latest drug developments news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Complete Response Letters

A Year Of Surprises Shakes Up Off-Patent Industry

After an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly compiled global sales ranking.

Biosimilars Generic Drugs

Coherus Nears FDA Filing Date For Humira Biosimilar

Coherus BioSciences has committed to oncology biosimilars over inflammation projects but is continuing to work towards a filing for biosimilar Humira (adalimumab) by 31 December. Armed with more than $200m of fresh capital, management discussed future business development plans.

Biosimilars Strategy

Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March

Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.

Commercial Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • InteKrin Therapeutics, Inc.
    • Coherus Intermediate Corp
UsernamePublicRestriction

Register